



## ASX ANNOUNCEMENT

**SYDNEY, 12 July 2012: Cellmid Limited (ASX: CDY)**

The attached document replaces the Appendix 3Y lodged this morning at 11.40am.

Contact:

Nicholas Falzon, Company Secretary

T +612 9299 0311

### **Cellmid Limited (ASX: CDY)**

Cellmid is an Australian biotechnology company developing innovative novel therapies and diagnostic tests for inflammatory diseases, heart attack and cancer. Cellmid holds the largest and most comprehensive portfolio of intellectual property related to midkine and midkine antagonists globally. The Company's most advanced clinical development program is for the treatment of acute myocardial infarction (AMI) utilising the midkine protein. Cellmid is also developing anti-midkine antibodies for the treatment of inflammatory and autoimmune disorders. In addition, Cellmid is commercialising midkine as a biomarker for cancer diagnosis. Elevated midkine concentration in the blood and other body fluids is strongly indicative of cancer. Cellmid's first product, the MK-ELISA, is a blood test that sensitively and accurately measures serum midkine levels.

### **Midkine (MK)**

Midkine is a multifunctional growth factor that is highly expressed during embryonic development. Midkine modulates many important biological interactions such as cell growth, cell migration and cellular adherence. These functions are relevant to cancer, inflammation, autoimmunity, ischemia, nerve growth/repair and wound healing. Midkine is barely detectable in healthy adults and only occurs as a consequence of the pathogenesis of a number of different disorders. Midkine expression is often evident very early in disease onset, even before any apparent physical symptoms. Accordingly, midkine is an important early marker for diagnosing cancers and autoimmune diseases. Finally, because midkine is only present in a disease context, targeting midkine does not harm normal healthy tissues.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity</b>	<b>Cellmid Limited</b>
<b>ABN</b>	<b>69 111 304 119</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Ms Maria Halasz
<b>Date of last notice</b>	15 <sup>th</sup> March 2012

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	A) Indirect B) Indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	A) Direct Capital Pty Ltd – entity controlled by Director as Trustee for the Halasz Family Retirement Fund B) Direct Capital Group Pty Ltd – entity controlled by the Director
<b>Date of change</b>	20 June 2012
<b>No. of securities held prior to change</b>	A) 2,725,250 fully paid ordinary shares 2,000,000 unlisted options (expiry 16 April 2013, ex price \$.05735 each 3,000,000 unlisted options (expiry 3 July 2013, (ex price \$.05735 each) 7,000,000 unlisted options (expiry 20 November 2014, exercise price \$0.056 each) B) Nil
<b>Class</b>	OPTIONS OVER ORDINARY SHARES
<b>Number acquired</b>	B) 5,000,000
<b>Number disposed</b>	NIL

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	NIL
<b>No. of securities held after change</b>	A) 2,725,250 fully paid ordinary shares 2,000,000 unlisted options (expiry 16 April 2013, ex price \$.05735 each) 3,000,000 unlisted options (expiry 3 July 2013, (ex price \$.05735 each) 7,000,000 unlisted options (expiry 20 November 2014, exercise price \$0.056 each) B) 5,000,000 unlisted options (expiry 15 June 2017, ex price \$.032 each)
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Options issued under Employee Share Scheme

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	
<b>Interest after change</b>	

+ See chapter 19 for defined terms.

**Part 3 – + Closed period**

<b>Were the interest in the securities or contracts detailed above traded during a + closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

25 June 2012

---

+ See chapter 19 for defined terms.